TORNTPHARM Q1 FY25 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,859 Cr
verified against source
Revenue YoY
10%
reported change
EBITDA
Pending
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Torrent Pharma delivered a solid Q1 FY25 with revenue of INR 2,859 crore (+10% YoY) driven by robust performance in India (+15%) and Brazil (+8% CC). EBITDA grew 14% YoY with margins at 32.3%. India business continues to outperform IPM (8%) with 15% growth led by chronic therapies (+14%), while Curatio integration is ahead of schedule with 19% growth. Brazil faced temporary headwinds from floods and 5% currency depreciation but should normalize in Q2. U.S. business remains stable at $31M but faces 13% YoY decline due to high base; Dahej site transfers are progressing. Indrad FDA inspection resulted in 5 observations with resolution expected by October. Gross margin of ~75% is sustainable. Management guides for mid-teens India growth, 12-13% Brazil growth, and mid-single digit Germany growth. U.S. profitability remains 2-3 years away pending new NDA approvals (5-10 expected this year). Key risk: FDA regulatory overhang on Indrad and prolonged U.S. turnaround timeline.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects low-teen to 15% growth for India business going forward, with Q1 at 15% serving as the higher end. Growth driven by chronic therapies, new launches including Vonoprazan/Kabvie, and improved field force productivity.
- Based on IQVIA MAT and quarterly data showing 12% growth for Torrent, management guides for 12-13% constant currency growth in Brazil over the medium term. Q1 was impacted by floods but should normalize from Q2.
- Response to FDA Form 483 (5 observations) has been submitted; management expects feedback by October with high likelihood of VAI/NAI classification for Indrad facility.
- Effective tax rate for FY25 is ~30%, same as Q1. From next fiscal year, transition to new tax regime in India should bring overall tax down to 26-27%.
Risks flagged
- U.S. FDA inspection at Indrad facility resulted in 5 observations, including repeat observations from prior inspection. Management expects resolution by October but acknowledges higher approval threshold given facility history.
- U.S. business is pre-R&D break-even currently. Management cannot provide timeline for post-R&D profitability, stating it depends on new NDA approvals spanning 2-3 years. Mid-single digit price erosion continues.
- Takeda has licensed Vonoprazan non-exclusively to multiple players including Zydus and Dr. Reddy's. While Torrent's Kabvie launched first and holds rank #1 as of June 2024, competitive pressure may intensify and impact market share trajectory.
- Brazilian Real depreciated ~5% in Q1 impacting reported revenues. Management states expenses also decline proportionally and Brazil represents only 10% of revenue, but further depreciation could affect profitability.
Key quotes
- FY 2026, I think I should be net cash, right? And therefore, whatever EBITDA generation or cash flow generation is happening, that would await capital allocation to be done, right? And acquisitions have been a integral part of our growth story.
- We would expect a response in the October timeframe from the FDA, and we think there's a high likelihood that the FDA would approve the plant, and the plant would be VAI or NAI. But we'd still like to wait and see, because there were five observations, and so we cannot be sure that it'll be 100%.
- Pre-R&D expenses, we are break even, kind of break even for the U.S. business. That's what Sanjay was implying, that we want to move towards a profitable path, as far as U.S. is concerned, post R&D.
Research modules